B of A Securities Maintains Neutral on Arcus Biosciences, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Zemansky maintains a Neutral rating on Arcus Biosciences (NYSE:RCUS) and raises the price target from $21 to $23.
September 05, 2023 | 4:34 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Arcus Biosciences' price target has been raised from $21 to $23 by B of A Securities, while maintaining a Neutral rating.
The news is directly about Arcus Biosciences. The raised price target indicates a positive outlook, but the Neutral rating suggests that the stock is fairly valued at the moment. This could lead to a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100